Back to Journals » Neuropsychiatric Disease and Treatment » Volume 11

The emerging role of bexarotene in the treatment of Alzheimer’s disease: current evidence

Authors Tousi B

Received 25 September 2014

Accepted for publication 8 December 2014

Published 5 February 2015 Volume 2015:11 Pages 311—315

DOI https://doi.org/10.2147/NDT.S61309

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 3

Editor who approved publication: Dr Roger Pinder


Babak Tousi

Cleveland Clinic Lou Ruvo Center for Brian Health, Neurological Institute, Cleveland, OH, USA

Abstract: In 2012, a novel approach to the treatment of Alzheimer’s disease was introduced, heralding a wave of excitement in the field of dementia. Bexarotene, a retinoid X receptor agonist, was shown to reverse neurodegeneration, improve cognition, and decrease levels of amyloid-ß in transgenic mice expressing familial Alzheimer disease mutations. Since then, there has been widespread discussion about bexarotene, as well as a number of follow-up studies. Bexarotene is a unique compound, as it is approved by the US Food and Drug Administration for other purposes and there are reasonable data to justify its mechanism of action in dementia. This review discusses these studies and the emerging role of bexarotene in the clinical field of Alzheimer’s dementia.

Keywords: repurposing, ApoE-targeted mice, amyloid, therapy, dementia

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]